Pulmatrix Quarterly Cash Flow Statements Chart
Quarterly
|
Annual
Pulmatrix Quarterly Cash Flow Statements Table
Quarterly
|
Annual
| Unit: USD | 2024-03-31 | 2023-12-31 | 2023-09-30 |
|---|---|---|---|
| cash flows from operating activities: | |||
| net income | 825,000 | -2,083,000 | -3,774,000 |
| adjustments to reconcile net income to net cash from operating activities: | |||
| depreciation and amortization | 59,000 | 38,000 | 32,000 |
| amortization of operating lease right-of-use asset | 215,000 | 170,000 | 394,000 |
| stock-based compensation | 198,000 | 197,000 | 206,000 |
| changes in operating assets and liabilities: | |||
| accounts receivable | 358,000 | -87,000 | -423,000 |
| prepaid expenses and other current assets | 30,000 | 157,000 | 120,000 |
| other long-term assets | 41,000 | 41,000 | 1,767,000 |
| accounts payable | -1,194,000 | 1,208,000 | -172,000 |
| accrued expenses and other current liabilities | 875,000 | -1,313,000 | 670,000 |
| operating lease liability | -144,000 | 342,000 | -2,540,000 |
| deferred revenue | -3,982,000 | -681,000 | -430,000 |
| net cash from operating activities | -2,719,000 | -2,011,000 | -4,142,000 |
| capex | 90,000 | -580,000 | -313,000 |
| free cash flows | -2,629,000 | -2,591,000 | -4,455,000 |
| cash flows from investing activities: | |||
| purchases of property and equipment | -154,000 | -305,000 | -313,000 |
| net cash from investing activities | -154,000 | -305,000 | -313,000 |
| cash flows from financing activities: | |||
| proceeds from issuance of common stock, net of issuance costs | 0 | 0 | |
| net cash from financing activities | 0 | 0 | |
| net decrease in cash, cash equivalents and restricted cash | -2,873,000 | -2,316,000 | -4,455,000 |
| cash, cash equivalents and restricted cash — beginning of period | 20,645,000 | 0 | 0 |
| cash, cash equivalents and restricted cash — end of period | 17,772,000 | -2,316,000 | -4,455,000 |
| reconciliation of cash, cash equivalents and restricted cash to the consolidated balance sheets: | |||
| cash and cash equivalents | 16,300,000 | -2,163,000 | -4,455,000 |
| restricted cash | 0 | ||
| long-term restricted cash | 1,472,000 | 0 | 0 |
| total cash, cash equivalents and restricted cash | 17,772,000 | -2,316,000 | -4,455,000 |
| supplemental disclosures of non-cash investing and financing information: | |||
| purchases of property and equipment not yet paid | 244,000 | -275,000 | |
| operating lease right-of-use asset obtained in exchange for operating lease obligation | |||
| loss on disposal of property and equipment | 0 | ||
| preferred stock issuance costs | |||
| operating lease right-of-use asset obtained in exchange for operating lease liability | -207,000 | ||
| conversion of preferred stock to common stock | |||
| fixed asset purchases in accounts payable |
We provide you with 20 years of cash flow statements for Pulmatrix stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as operating cash flows, cash levels, capital expenditures, profits, stock-based compensations and profit margins. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of Pulmatrix stock. Explore the full financial landscape of Pulmatrix stock with our expertly curated income statements.
The information provided in this report about Pulmatrix stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.